|Bid||0.0950 x 0|
|Ask||0.1050 x 0|
|Day's Range||0.1000 - 0.1050|
|52 Week Range||0.0150 - 0.1750|
|Beta (5Y Monthly)||0.52|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma") and Solarvest BioEnergy Inc. (TSX-V: SVS) ("Solarvest") (collectively, the "Parties"), are pleased to announce that, further to their press release of May 7, 2019, the Parties have agreed to amendments to the Collaborative Research and Development Agreement (the "Research Agreement") designed to accelerate progress of the research project that Solarvest is carrying out (the "CBD Research Project"). Under the amended Research Agreement, FSD Pharma has agreed to issue additional class B subordinate voting shares ("FSD Shares") to Solarvest, which will enable Solarvest to fund the CBD Research Project. In addition, Solarvest has appointed Dr. Edward J. Brennan, Jr., M.D., FACS ("Dr. Brennan"), currently the President of FSD Pharma’s BioSciences Division, to the board of directors of Solarvest.